| TA178 |
Renal cell carcinoma (TA178) |
|
-
-
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab, sorafenib and temsirolimus are not recommended as first drug treatments for people with advanced and/or metastatic renal cell carcinoma.
Sorafenib and sunitinib are not recommended as second drug treatments for people with advanced and/or metastatic renal cell carcinoma.
Specialists should not stop prescribing bevacizumab, sorafenib, sunitinib and temsirolimus for people who were already taking them when the guidance was issued. These people should be able to carry on taking bevacizumab, sorafenib, sunitinib and temsirolimus until they and their specialists decide that it is the right time to stop treatment.
-
Other information
How this guidance was produced
Background information
This page was last updated: 08 December 2010
-
-
Guidance formats
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- Patient version (MS Word)
- TA178 Bevacizumab (triniaeth gyntaf), sorafenib (triniaeth gyntaf ac ail driniaeth), sunitinib (ail driniaeth) a temsirolimus (triniaeth gyntaf) ar gyfer carsinoma celloedd arennol datblygedig a/neu fetastatig: deall canllawiau NICE (fformat MS Word)
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
